Coloplast A/S
https://www.coloplast.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coloplast A/S
MTI 100: Macro Challenges Make Demands Of Newly Resilient Medtechs
Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.
Deal Watch: Novo Nordisk Builds On Metabolic Strength Acquiring Partner Embark
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
Minute Insight: Coloplast Adds Icelandic Wound Care Innovator Kerecis For $1.3BN
Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.
Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and much of the low-hanging therapeutic fruit already picked, a growing number of firms are taking a different, pragmatic approach. They are looking in a new light at existing compounds that may have been dropped in development for reasons that are no longer insuperable, or even withdrawn from the market. One such firm is Lumavita, whose CEO Nicholas Benedict spoke to Scrip's companies editor Eleanor Malone.
Company Information
- Industry
-
Medical Devices
- Surgical Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Atos Medical, Comfort Medical, LLC
- IncoCare
- Mpathy Medical
- SAS Lilial
- Nine Continents Medical, Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice